Table 2.
Antiviral activity of potent leads against different serotypes of EV-D68 and EV-A71 in RD cells
EV-strains |
![]() |
![]() |
![]() |
![]() |
|
---|---|---|---|---|---|
EV-D68 | US/KY/14-18953 (Clade D) | EC50 = 0.1 ± 0.03 CC50 = 200.0 ± 10.8 SI50 = 2000 |
EC50 = 0.2 ± 0.1 CC50 = 236.3 ± 20.5 SI50 = 1183 |
EC50 = 0.03 ± 0.001 CC50 = 160.9 ± 12.8 SI50 = 5363.3 |
EC50 = 1.0 ± 0.1 CC50 = 116.6 ± 16.1 SI50 = 116.6 |
US/MO/14-18947 (Clade B1) | EC50 = 0.1 ± 0.03 CC50 = 200.0 ± 10.8 SI50 = 2000 |
EC50 = 0.2 ± 0.05 CC50 = 236.3 ± 20.5 SI50 = 1183 |
EC50 = 0.07 ± 0.01 CC50 = 160.9 ± 12.8 SI50 = 2298.6 |
EC50 = 0.4 ± 0.2 CC50 = 116.6 ± 16.1 SI50 = 291.5 |
|
US/MO/14-18949 (Clade B1) | EC50 = 0.1 ± 0.02 CC50 = 200.0 ± 10.8 SI50 = 2000 |
EC50 = 0.2 ± 0.1 CC50 = 236.3 ± 20.5 SI50 = 1183 |
EC50 = 0.08 ± 0.01 CC50 = 160.9 ± 12.8 SI50 = 2011.3 |
EC50 = 0.7 ± 0.4 CC50 = 116.6 ± 16.1 SI50 = 166.6 |
|
US/IL/14-18956 (Clade B2) | EC50 = 0.04 ± 0.01 CC50 = 200.0 ± 10.8 SI50 = 5000 |
EC50 = 0.2 ± 0.04 CC50 = 236.3 ± 20.5 SI50 = 1183 |
EC50 = 0.07 ± 0.01 CC50 = 160.9 ± 12.8 SI50 = 2298.6 |
EC50 = 0.4 ± 0.1 CC50 = 116.6 ± 16.1 SI50 = 291.5 |
|
US/IL/14-18952 (Clade B2) | EC50 = 0.04 ± 0.01 CC50 = 200.0 ± 10.8 SI50 = 5000 |
EC50 = 0.2 ± 0.03 CC50 = 236.3 ± 20.5 SI50 = 1183 |
EC50 = 0.09 ± 0.01 CC50 = 160.9 ± 12.8 SI50 = 1787.8 |
EC50 = 0.7 ± 0.02 CC50 = 116.6 ± 16.1 SI50 = 166.6 |
|
EV-A71 | Tainan/4643/1998 | EC50 = 0.1 ± 0.04 CC50 = 200.0 ± 10.8 SI50 = 2000 |
EC50 = 0.2 ± 0.03 CC50 = 236.3 ± 20.5 SI50 = 1183 |
EC50 = 0.2 ± 0.04 CC50 = 160.9 ± 12.8 SI50 = 804.5 |
EC50 = 7.4 ± 1.7 CC50 = 236.3 ± 20.5 SI50 = 31.9 |
USA/CT/2016-19519 | EC50 = 0.06 ± 0.01 CC50 = 200.0 ± 10.8 SI50 = 3333.3 |
EC50 = 0.1 ± 0.04 CC50 = 236.3 ± 20.5 SI50 = 2363 |
EC50 = 0.06 ± 0.01 CC50 = 160.9 ± 12.8 SI50 = 2681.7 |
EC50 = 1.3 ± 0.4 CC50 = 236.3 ± 20.5 SI50 = 181.8 |
|
A71 MP4 | EC50 = 0.1 ± 0.03 CC50 = 200.0 ± 10.8 SI50 = 2000 |
EC50 = 0.3 ± 0.02 CC50 = 236.3 ± 20.5 SI50 = 787.7 |
EC50 = 0.2 ± 0.04 CC50 = 160.9 ± 12.8 SI50 = 804.5 |
EC50 = 2.0 ± 0.3 CC50 = 236.3 ± 20.5 SI50 = 118.2 |
Antiviral efficacy EC50 was determined using the CPE assay in RD cells.
Cytotoxicity CC50 was determined using the neutral red uptake method.
N.T.= not tested. The results are the mean ± standard deviation of three repeats. SI50 = selectivity index (CC50/EC50).